Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CFO Steven Cook sold 17,950 shares of Omada Health stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $18.13, for a total transaction of $325,433.50. Following the transaction, the chief financial officer directly owned 169,259 shares in the company, valued at approximately $3,068,665.67. This represents a 9.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Omada Health Stock Up 1.6%
Shares of NASDAQ OMDA opened at $18.90 on Friday. The company has a market capitalization of $1.12 billion and a PE ratio of -70.00. The stock’s 50 day moving average price is $16.35 and its 200-day moving average price is $14.80. Omada Health, Inc. has a twelve month low of $10.28 and a twelve month high of $26.92.
Omada Health (NASDAQ:OMDA – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%.The company had revenue of $78.05 million during the quarter. As a group, research analysts expect that Omada Health, Inc. will post -0.01 EPS for the current fiscal year.
Institutional Investors Weigh In On Omada Health
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Omada Health in a report on Thursday, June 4th. Wall Street Zen downgraded shares of Omada Health from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. Evercore reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of Omada Health in a research report on Friday, May 8th. BMO Capital Markets dropped their target price on shares of Omada Health from $27.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, March 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of Omada Health in a research note on Friday, May 8th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Omada Health has a consensus rating of “Moderate Buy” and an average target price of $22.91.
View Our Latest Research Report on Omada Health
About Omada Health
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Featured Stories
- Five stocks we like better than Omada Health
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
